Login to Your Account

Vical, Astellas Begin Phase III Transplant Trial of CMV Vaccine

By Catherine Shaffer
Staff Writer

Tuesday, June 25, 2013

Vical Inc. and Astellas Pharma Inc. began a Phase III trial of Transvax, a vaccine for cytomeglovirus (CMV), in 500 hematopoietic cell transplant recipients, with Astellas taking the lead and Vical providing development, regulatory and manufacturing support.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription